Cost-Effectiveness of Molecular Method Diagnostic for Rapid Detection of Antibiotic-Resistant Bacteria

Published Feb 21, 2022

Bianca C. Salvador, Federal University of Parana, Parana, Brazil, Rosa C. Lucchetta, University of Parana, Parana, Brazil, Flávia M. Sarti, School of Arts, Sciences, and Humanities, University of São Paulo, São Paulo, Brazil, Fernando F. Ferreira, Department of Physics, School of Philosophy, Sciences, and Letters, University of São Paulo, São Paulo, Brazil, Esteban F. Tuesta, School of Arts, Sciences, and Humanities, University of São Paulo, São Paulo, Brazil, Bruno S. Riveros, MAPESolutions, Parana, Brazil, Keite S. Nogueira, Clinical Hospital, Federal University of Parana, Parana, Brazil, Bernardo M.M. Almeida, Clinical Hospital, Federal University of Parana, Parana, Brazil, Helena H.L. Borba, Federal University of Parana, Parana, Brazil, Astrid Wiens, Federal University of Parana, Parana, Brazil.

Antimicrobial drug resistance is a serious worldwide public health problem, because of its high mortality rate and complex clinical management. Centers for Disease Control and Prevention, in 2013, estimated that more than 2 million infections per year were caused by resistant pathogens, 23.000 resulting in death. Therefore, in 2017, World Health Organization listed the global priority of antibiotic-resistant bacteria aiming to guide research. However, besides management difficulties, diagnostic by itself represents an important point of care. Following international guidelines, the conventional method demand days to weeks until the final result, on the other hand, molecular methods provide accurate and faster identification of resistant strains, but at higher costs.

The aim of this study was to perform a cost-effectiveness analysis (CEA) of the molecular diagnostic method associated with conventional diagnostic method compared with the conventional method alone, for the detection of resistant profile in bacteremia, from the perspective of the Brazilian Public Health System, in intensive care units. To achieve this goal, clinical parameters regarding methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Gram-negative bacteria (CRGNB), and vancomycin-resistant Enterococcus spp. (VRE) infections were collected from searches on PubMed, Scopus, and SciELO, using specific keywords, followed by building a dynamic model which allows CEA, calibrated and validated according to international recommendations. The incremental cost-effectiveness ratio of the associated methods (molecular and conventional) compared with the conventional alone was calculated using the outcomes “avoided death” and “avoided resistant infections.” Please read the full article here.

Related Stories

ISPOR Chief Science Officer Dr Laura Pizzi Named to NJBIZ's 2026 People to Watch in Healthcare List

Jul 29, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) is proud to announce its Chief Science Officer, Laura Pizzi, PharmD, MPH, has been recognized by NJBIZ as one of its 2026 People to Watch in Healthcare.

ISPOR Announces the Healthcare Investment Summit 2026

Jul 20, 2026

ISPOR announced their inaugural Healthcare Investment Summit 2026, which will bring together healthcare investors, founders, pharma and device executives, policy experts, health economists, and access leaders on September 22–23, 2026, in San Francisco to examine the critical factors shaping investment decisions across the healthcare landscape.

New ISPOR Report Introduces "IMPACT" Framework to Guide Value-Based Healthcare Implementation

Jul 13, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of an ISPOR Special Task Force Report offering good practice recommendations and a new "IMPACT" framework for integrating health economics and outcomes research (HEOR) methods into value-based healthcare implementation.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×